📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Anuh Pharma Q3 FY26 PAT Jumps 30% YoY to ₹13.45 Cr; Revenue Up 23.6%
Anuh Pharma reported a strong quarterly performance for the period ended December 31, 2025, with revenue from operations growing 23.6% YoY to ₹197.18 crore. Net profit for the quarter rose significantly by 30% YoY to ₹13.45 crore, aided by improved EBITDA margins which stood at 10.60%. On a sequential basis, the profit growth was even more pronounced, surging 76.7% compared to the preceding quarter (Q2 FY26). While the nine-month revenue is up 23%, the cumulative net profit remains lower than the previous year due to higher input costs incurred in the first half of the fiscal year.
Key Highlights
Revenue from operations increased by 23.6% YoY to ₹197.18 crore in Q3 FY26.
Net Profit (PAT) grew by 30% YoY to ₹13.45 crore, with a sharp 76.7% sequential recovery from Q2 FY26.
EBITDA margins improved to 10.60% in Q3 FY26 compared to 9.86% in the same quarter last year.
Earnings Per Share (EPS) for the quarter stood at ₹1.34, adjusted for the 1:1 bonus share issuance in July 2025.
The company recognized a one-time incremental obligation of ₹48.31 lakhs related to the implementation of New Labour Codes.
👀 What to Watch
The strong quarterly recovery in margins and bottom-line growth indicates a positive shift in operational efficiency. Investors should monitor the sustainability of these margins in the upcoming quarter to confirm a full turnaround from the high-cost environment seen earlier in the year.
Anuh Pharma Q3 FY26 PAT Jumps 30% YoY to ₹13.45 Cr; Revenue Up 23.6%
Anuh Pharma reported a robust performance for Q3 FY26, with revenue from operations growing 23.6% YoY to ₹197.18 crore. Net profit for the quarter rose 30% YoY to ₹13.45 crore, marking a significant sequential recovery from ₹7.61 crore in Q2 FY26. EBITDA margins improved to 10.60% from 6.92% in the previous quarter, indicating better operational efficiency. However, cumulative 9-month PAT remains 15.8% lower than the previous year at ₹29.36 crore, despite a 22.9% growth in 9-month revenue.
Key Highlights
Revenue from operations increased 23.6% YoY to ₹19,717.81 Lakhs in Q3 FY26.
Net Profit (PAT) grew 30% YoY to ₹1,345.10 Lakhs, with a massive 76.7% sequential jump from Q2 FY26.
EBITDA margins expanded to 10.60% in Q3 FY26 compared to 9.86% in Q3 FY25 and 6.92% in Q2 FY26.
9M FY26 Revenue grew 22.9% to ₹56,954.02 Lakhs, though 9M PAT is down 15.8% YoY at ₹2,936.47 Lakhs.
The company recognized a one-time estimated obligation of ₹48.31 Lakhs due to the implementation of New Labour Codes.
👀 What to Watch
The strong sequential recovery in margins and profitability suggests that the company has successfully navigated previous cost pressures. Investors should watch for the sustainability of these double-digit EBITDA margins in the upcoming quarters.
Anuh Pharma Receives EDQM Approval (CEP) for Sulfadimethoxine API
Anuh Pharma Limited has successfully obtained the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its product, Sulfadimethoxine. This regulatory milestone signifies that the company's Active Pharmaceutical Ingredient (API) meets the stringent quality standards required for the European market. The approval is expected to facilitate expanded access to regulated international markets and enhance the company's export potential. This development strengthens Anuh Pharma's position as a reliable supplier of high-quality APIs globally.
Key Highlights
Received Certificate of Suitability (CEP) from the EDQM for Sulfadimethoxine.
Approval validates compliance with stringent European regulatory and quality standards.
Enables the company to expand its market reach into highly regulated pharmaceutical regions.
Expected to improve supply security and reliability for global pharmaceutical customers.
Strengthens the company's API portfolio for international trade.
👀 What to Watch
Investors should monitor the potential increase in export revenue from the European market in future quarters. This regulatory win is a positive indicator of the company's manufacturing quality and long-term growth prospects in regulated markets.
